rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Neuraxis, Inc.

NRXS · NYSE American

Health CareMedical DevicesJust started moving

NRXS stood above a rising 150-day average in 41 of the last 52 weekly readings, including each of the last 1 week. It is 11.8% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Just started moving
Weeks in an uptrend
1 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$1.8M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
30 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1.7M$0$904KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months9
Sale orders, 12 months0
Buyers · sellers5 · 0
WhoDidSharesTraded
Timothy Robert HenrichsChief Financial Officerbought1,937at $4.848 Oct 2026filed 8 Oct 2026
Thomas Joeseph CarricoCRO, CCO, CPObought328at $4.848 Oct 2026filed 8 Oct 2026
Brian Allen CarricoChief Executive Officerbought268at $4.848 Oct 2026filed 8 Oct 2026
Brian Allen CarricoChief Executive Officerbought8,060at $1.961 Apr 2026filed 3 Apr 2026
Thomas Joeseph CarricoCRO, CCO, CPObought667at $1.961 Apr 2026filed 3 Apr 2026
Timothy Robert HenrichsChief Financial Officerbought7,593at $1.961 Apr 2026filed 3 Apr 2026
Brian Hannasch10% ownerbought40,000at $4.9212 Feb 2026filed 13 Feb 2026
Brian Hannasch10% ownerbought40,000at $4.6511 Feb 2026filed 13 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders30+6 on the quarter
New · exited9 · 3
Reported value$19.1M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
AIGH Capital Management LLCadded · filed 7 Aug 2026519,938$3.8M+119,938+30.0%
Rosalind Advisors, Inc.added · filed 14 Aug 2026508,055$3.0M+221,917+77.6%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026335,793$2.5M+109,926+48.7%
MONEY CONCEPTS CAPITAL CORPadded · filed 4 Aug 2026228,029$1.7M+2,474+1.1%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026169,400$1.2M+92,446+120.1%
MARSHALL WACE, LLPadded · filed 13 Aug 2026128,755$941K+50,060+63.6%
PARSONS CAPITAL MANAGEMENT INCadded · filed 24 Jul 2026117,808$861K+1,082+0.9%
Panoramic Capital, LLCreduced · filed 14 Aug 2026115,000$841K-75,000−39.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 202696,361$705K+3,256+3.5%
CITADEL ADVISORS LLCnew · filed 14 Aug 202685,053$622K+85,053
30 Sep 2023 – 30 Jun 2026
71829Sep 23Jun 24Mar 25Sep 25Jun 26

Everyone who traded it

Brian Allen Carrico Company insiderChief Executive Officer · last 8 Oct 20262 · 0
Thomas Joeseph Carrico Company insiderCRO, CCO, CPO · last 8 Oct 20262 · 0
Timothy Robert Henrichs Company insiderChief Financial Officer · last 8 Oct 20262 · 0
Adrian Miranda Company insiderCMO, SVP Science & Tech · last 24 Aug 20260 · 0
Bradley Mitchell Watkins Company insiderDirector · last 13 Aug 20260 · 0
Gil Aharon Company insiderDirector · last 13 Aug 20261 · 0
Jane Elizabeth Keyser Company insiderDirector · last 13 Aug 20260 · 0
Kristin A. Ferge Company insiderDirector · last 13 Aug 20260 · 0
Brian Hannasch Company insider10% owner · last 12 Feb 20264 · 1
Masimo Corp Company insider10% owner · last 1 Jul 20250 · 1

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202584.2%
Operating profit marginFY 2025 · to 31 Dec 2025-219%
Free cash flow marginFY 2025 · to 31 Dec 2025-181%
Debt to equityFY 2025 · to 31 Dec 20250.04×
Research spendFY 2025 · to 31 Dec 202513.8%
Share count trendFY 2025 · to 12 Mar 20265.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$5.0M
Free cash flowFY 2025 · to 31 Dec 2025−$6.5M

Analyst forecasts

No analyst forecasts yet.